ECP
SWTX

Empyrean Capital Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Empyrean Capital Partners’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-245,000
Closed -$10.8M – 83
2025
Q1 		$10.8M Buy
+245,000
New +$11.3M 0.38% 41

Other funds holding SWTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Empyrean Capital Partners's SWTX Position: Q2 2025 in Review

Empyrean Capital Partners sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 245,000 shares — an estimated $10.8M sold.

Empyrean Capital Partners first reported a position in SWTX in Q1 2025 and held it in 1 quarter. The position peaked at $10.8M in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Empyrean Capital Partners reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Empyrean Capital Partners sold 245,000 SpringWorks Therapeutics shares in Q2 2025, an estimated $10.8M.
  • Empyrean Capital Partners first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 1 quarter.
  • Empyrean Capital Partners's SpringWorks Therapeutics position peaked at $10.8M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Empyrean Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.